by Lisa Stiffler on Nov 11, 2026 at 2:31 pmNovember 11, 2026 at 2:31 pm

Lila Bio, a startup spun out of Nobel laureate David Baker’s lab at the University of Washington, has received a $3.65 million grant from the National Institutes of Health to develop a treatment for pulmonary hypertension.
The condition causes high blood pressure in the arteries that carry blood from the heart to the lungs. It forces the heart to work harder and can lead to heart failure.
The Small Business Innovation Research fast-track award supports Lila’s efforts to develop a protein-based treatment for pulmonary hypertension that could be given by injection a few times a year.
“Most approved therapies only manage symptoms, such as vasodilators,” Lila CEO







